Desmopressin for Nocturnal Polyuria in Multiple Sclerosis: A Hidden Sodium Drop
A drug that could finally let her sleep through the night carries a hyponatremia risk whose early symptoms — fatigue, fogginess — are indistinguishable from the disease she already has.
Renata V., a 47-year-old hospice nurse who has worked night shifts for eleven years and always considered her own sleep negotiable in a way her patients' comfort never was, was diagnosed with relapsing multiple sclerosis nine years ago and has managed reasonably well on ocrelizumab, with mild residual fatigue she has mostly learned to plan her rotations around. For the past six months, nocturnal polyuria has taken over what sleep she used to reliably get on her nights off: she wakes four to five times to void, passing what her bladder diary shows is nearly 70% of her total daily urine output between midnight and six a.m., a genuine physiologic shift rather than simply drinking poorly-timed fluids, which she has already adjusted — cutting off all fluids after 6 p.m. for six weeks — without any real improvement in how often she wakes.
Desmopressin is an effective, well-established treatment for nocturnal polyuria, and Eckford et al.'s work in women with multiple sclerosis and nocturia established real reductions in nocturnal frequency and volume in exactly this population. The number that should govern how she is monitored, though, comes from Valiquette et al.'s double-blind crossover trial in multiple sclerosis: it cut the proportion of nights disturbed by nocturia from 97% to 66% and lengthened the longest uninterrupted stretch of sleep from under four hours to nearly six — and four of its seventeen patients withdrew after developing hyponatremia that was asymptomatic or nearly so, caught because the trial was drawing labs on a fixed schedule rather than waiting for anyone to report feeling unwell. Roughly one in four, which is not a footnote-sized risk. That last detail is the one that matters most for Renata specifically: hyponatremia's earliest symptoms are fatigue, cognitive slowing, and a kind of generalized fogginess, which is also a near-exact description of her own baseline MS symptom she has spent years learning to distinguish from anything else, on a body clock already scrambled by a decade of night shifts. At 47 she sits well clear of the age band where desmopressin's sodium risk climbs steeply, which is genuinely reassuring and almost entirely beside the point: the problem is not the size of her risk but her own inability to feel it arriving.
MS clinic, six months of unrelenting nocturia
I want to start desmopressin. Six months of losing most of a night's sleep four to five times over is a real, ongoing harm to her quality of life and, frankly, her job performance, and the trials in comparable multiple sclerosis populations showed genuine benefit — Valiquette's cut the proportion of disturbed nights from 97% to 66%.
The efficacy result is real, but I'd point at the same trial's safety column rather than its headline — four of seventeen patients withdrew from it after developing hyponatremia, asymptomatic or nearly so. That's not a minority footnote, it's close to one in four.
For most patients, that's still a risk caught on routine labs before symptoms appear. For Renata specifically, the earliest warning signs of hyponatremia — fatigue, cognitive fog — are indistinguishable from a baseline symptom she already has and has learned to tune out. I'm not opposed to the drug; I want us to build monitoring around the fact that she can't rely on noticing it herself.
That's the right frame, and it changes what adequate monitoring looks like for her compared to a typical patient. I'd start desmopressin with scheduled sodium checks — not just as-needed based on symptoms she's told to watch for, since we've just established she can't reliably distinguish those symptoms from her existing baseline.
A sodium check at one week and one month, rather than the usual as-needed approach, catches an asymptomatic drop the way the trial caught it in four of its own seventeen — before it becomes anything she'd need to notice on her own at all.
Agreed: start low-dose desmopressin with scheduled, non-symptom-triggered sodium checks at one week and one month, given Renata's specific inability to reliably distinguish early hyponatremia symptoms from her baseline MS fatigue.
Not agreed: the neurologist would have used the standard as-needed monitoring approach most patients receive, and views the scheduled-check protocol as more intensive than routine practice requires — accepted as the more cautious path anyway, given the specific overlap between hyponatremia's warning signs and Renata's own baseline symptom that neither the trial nor the standard monitoring approach was built to anticipate.